<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01731158</url>
  </required_header>
  <id_info>
    <org_study_id>C-II-008</org_study_id>
    <secondary_id>2011-005939-78</secondary_id>
    <nct_id>NCT01731158</nct_id>
  </id_info>
  <brief_title>Sequential Therapy in Metastatic Renal Cell Carinoma</brief_title>
  <acronym>BERAT</acronym>
  <official_title>A Prospective, Open-label, Multicenter, Randomized Phase II Trial: Sequential Therapy With BEvacizumab, RAd001 (Everolimus) and Tyrosinekinase Inhibitors (TKI) in Metastatic Renal Cell Carcinoma (mRCC) (BERAT Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central European Society for Anticancer Drug Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central European Society for Anticancer Drug Research</source>
  <brief_summary>
    <textblock>
      Sequential therapy with BEvacizumab, RAd001 (everolimus) and Tyrosinekinase inhibitors (TKI)&#xD;
      in metastatic renal cell carcinoma (mRCC)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective, open label, randomized multicenter phase-II study to evaluate&#xD;
      progression free survival (PFS) in 2nd line treatment in patients with locally advanced or&#xD;
      metastatic clear-cell renal cell cancer (cc-RCC) receiving everolimus (arm A) in comparison&#xD;
      to a tyrosine-kinase inhibitor (TKI) (arm B). Following 2nd line treatment, patients will be&#xD;
      switched to a TKI in arm A and everolimus in arm B. All patients will receive bevacizumab as&#xD;
      standardized first-line treatment.&#xD;
&#xD;
      Another key element of the study is the analysis of predictive biomarkers, which will be&#xD;
      performed in serum and tumor tissue, respectively. Serum samples will be collected at&#xD;
      prespecified timepoints throughout the study and analysed by SELDI-TOF-MS and DIGE. Candidate&#xD;
      proteins are thought to predict therapeutic outcome and candidates are subject for target&#xD;
      validation by Western Blot or ELISA. In addition, formalin-fixed paraffin-embedded (FFPE)&#xD;
      tumor tissue will be collected prospectively and analysed for micro RNA (miRNA). Candidate&#xD;
      miRNAs that predict therapeutic outcome will be validated by quantitative RT-PCR.&#xD;
      Furthermore, circulating tumor cells (CTCs) will be generated from blood drawings during&#xD;
      routine visits. The primary objective is to correlate the marker profile defined from the&#xD;
      FFPE tissue with the profile obtained from CTCs in order to validate expression based markers&#xD;
      ant their change during different treatment lines.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS rate of 2nd line treatment at 6 months after randomisation</measure>
    <time_frame>6 months after randomisation</time_frame>
    <description>PFS rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS for 2nd line treatment</measure>
    <time_frame>after completion of second-line treatment (expected median treatment 1st and 2nd line: 16 months)</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS for each treatment given</measure>
    <time_frame>after completion of each treatment line (expected median treatment duration 1st line: 11 months, 2nd line: 5 months, 3rd line: 6 months)</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>after death of patient</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number and severity (CTCAE 4.0) adverse events</measure>
    <time_frame>continuously throughout trial</time_frame>
    <description>AE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in quality of life throughout the Trial using FKSI questionnaires</measure>
    <time_frame>continuously throughout trial (baseline, week 5, week 11, every 12 weeks, end of treatment for all treatment lines via FKSI-10 questionnaire)</time_frame>
    <description>quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR for each treatment given</measure>
    <time_frame>after completion of each treatment line (expected median treatment duration 1st line: 11 months, 2nd line: 5 months, 3rd line: 6 months)</time_frame>
    <description>ORR</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Metastatic Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>arm A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>sequential therapy with approved drugs&#xD;
Avastin in combination with Roferon-A (first-line), Afinitor (second-line) and a TKI (Sutent, Nexavar or Votrient) (third-line)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>sequential therapy with approved drugs&#xD;
Avastin in combination with Roferon-A (first-line), a TKI (Sutent, Nexavar or Votrient) (second-line) and Afinitor (third-line)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avastin in combination with Roferon-A</intervention_name>
    <arm_group_label>arm A</arm_group_label>
    <arm_group_label>arm B</arm_group_label>
    <other_name>Bevacizumab in combination with Interfereon-alfa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afinitor</intervention_name>
    <arm_group_label>arm A</arm_group_label>
    <arm_group_label>arm B</arm_group_label>
    <other_name>Everolimus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TKI: Sutent, Nexavar or Votrient</intervention_name>
    <description>TKI</description>
    <arm_group_label>arm A</arm_group_label>
    <arm_group_label>arm B</arm_group_label>
    <other_name>Sunitinib, Sorafenib or Pazopanib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed Informed Consent&#xD;
&#xD;
          -  Documented progressive disease prior to study inclusion.&#xD;
&#xD;
          -  Adult males and females: ≥ 18 years of age.&#xD;
&#xD;
          -  Metastatic or locally advanced RCC, not amendable to surgery with curative intention.&#xD;
&#xD;
          -  ECOG performance status 0-1.&#xD;
&#xD;
          -  Patients with measurable disease (at least one uni-dimensionally measurable target&#xD;
             lesion by CT-scan or MRI) according to Response Evaluation Criteria in Solid Tumors&#xD;
             (RECIST 1.1) If prior palliative radiotherapy to metastatic lesions: ≥ 1 measurable&#xD;
             lesion that has not been irradiated. Patients with bone lesions as the only measurable&#xD;
             lesion are eligible, provided that lesions consist of soft tissue, which is assessed&#xD;
             via CT or MRI.&#xD;
&#xD;
          -  Prior radiotherapy and surgery are allowed if completed 4 weeks (for minor surgery 2&#xD;
             weeks) prior to start of treatment and patient recovered from toxic effects.&#xD;
&#xD;
          -  Modified MSKCC risk (according to Heng): good or intermediate.&#xD;
&#xD;
          -  White blood cell count (WBC) ≥ 4x10*9/L with neutrophils ≥ 1.5 x 10*9/L, platelet&#xD;
             count ≥ 100x10*9/L, hemoglobin ≥ 9 g/dL.&#xD;
&#xD;
          -  Total bilirubin ≤ 2 x upper limit of normal.&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 x upper limit of normal, or ≤ 5 x upper limit of normal in case of&#xD;
             liver metastases.&#xD;
&#xD;
          -  Serum creatinine ≤ 2 x upper limit of normal or calculated creatinine clearance &gt;30&#xD;
             ml/min.&#xD;
&#xD;
          -  International Normalized Ratio (INR) ≤1.5 except for patients on stable anticoagulant&#xD;
             therapy. Activated partial thromboplastin time (aPTT) ≤1.5 times upper limit of normal&#xD;
             (ULN) or greater than the lower limit of the therapeutic range. Note: The use of&#xD;
             full-dose oral or parenteral anticoagulants is permitted as long as the INR or aPTT is&#xD;
             within therapeutic limits (according to the medical standard in the institution) and&#xD;
             the patient has been on a stable dose of anticoagulants for at least two weeks at the&#xD;
             treatment start.&#xD;
&#xD;
          -  Adequate cardiac function (left ventricular ejection fraction ≥50% as assessed by&#xD;
             ECHO)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any investigational drug within the 30 days before inclusion.&#xD;
&#xD;
          -  Known or suspected allergy or hypersensitivity reaction to any of the components of&#xD;
             study treatments or their excipients.&#xD;
&#xD;
          -  Pregnancy (absence to be confirmed by beta-hCG test) or lactation period.&#xD;
&#xD;
          -  Men or women of child-bearing potential who are sexually active and unwilling to use a&#xD;
             highly effective method of contraception (Pearl index &lt; 1%) during the trial. Oral&#xD;
             contraceptives are acceptable if a barrier method is applied in conjunction.&#xD;
&#xD;
          -  Clinically symptomatic brain or meningeal metastasis (known or suspected), unless&#xD;
             completion of local therapy for at least 3 months with discontinuation of steroids&#xD;
             prior to start of treatment.&#xD;
&#xD;
          -  Cardiac arrhythmias requiring anti-arrhythmics (excluding beta blockers, digoxin or&#xD;
             digitoxin).&#xD;
&#xD;
          -  History of any of the following cardiac events within the past 6 months:&#xD;
&#xD;
               1. myocardial infarction (including severe/unstable angina),&#xD;
&#xD;
               2. coronary/peripheral artery bypass graft,&#xD;
&#xD;
               3. congestive heart failure (CHF) (NYHA Class III, or IV),&#xD;
&#xD;
               4. cerebrovascular accident,&#xD;
&#xD;
               5. transient ischemic attack,&#xD;
&#xD;
               6. pulmonary embolism, abdominal or tracheo-oesophageal fistula, gastrointestinal&#xD;
                  perforation, or intra-abdominal abscess&#xD;
&#xD;
          -  Hemorrhage ≥ grade 3 or clinically significant hemoptysis within the past 4 weeks&#xD;
&#xD;
          -  Uncontrolled severe hypertension (failure of diastolic blood pressure to fall below 90&#xD;
             mm Hg despite the use of ≥ 3 anti-hypertensive drugs).&#xD;
&#xD;
          -  History of relevant pulmonary hypertension or interstitial lung disease or severely&#xD;
             impaired lung function.&#xD;
&#xD;
          -  Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease or&#xD;
             chronic diarrhea.&#xD;
&#xD;
          -  Previous malignancy (other than renal cell cancer) in the last 3 years, except basal&#xD;
             cell cancer of the skin, pre-invasive cancer of the cervix, T1a prostate carcinoma or&#xD;
             superficial bladder tumor [Ta, Tis and T1].&#xD;
&#xD;
          -  History of organ allograft.&#xD;
&#xD;
          -  Significant disease which, in the investigator's opinion would exclude the patient&#xD;
             from the study.&#xD;
&#xD;
          -  Medication that is known to interfere with any of the agents applied in the trial.&#xD;
&#xD;
          -  Patients with a serious non-healing wound, ulcer or bone fracture.&#xD;
&#xD;
          -  Patients with a history of seizure(s) not controlled with standard medical therapy.&#xD;
&#xD;
          -  Patients receiving chronic systemic treatment with corticosteroids (dose of &gt; 20&#xD;
             mg/day methylprednisone equivalent) or another immune-suppressive agent. Inhaled and&#xD;
             topical steroids are acceptable.&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity.&#xD;
&#xD;
          -  Medical or psychological conditions that would not permit the patient to complete the&#xD;
             study or sign informed consent.&#xD;
&#xD;
          -  Significant vascular disease (e.g. aortic aneurysm, aortic dissection), or symptomatic&#xD;
             peripheral vascular disease.&#xD;
&#xD;
          -  Evidence or history of recurrent thromboembolism (&gt;1 episode of deep venous&#xD;
             thrombosis/peripheral embolism ≥ CTCAE Grade 3) during the past 2 years, bleeding&#xD;
             diathesis or coagulopathy.&#xD;
&#xD;
          -  Poorly controlled diabetes as defined by fasting serum glucose &gt; 2.0 x ULN.&#xD;
&#xD;
          -  Active (acute or chronic) or uncontrolled infection of bacterial, mycotic or viral&#xD;
             genesis.&#xD;
&#xD;
          -  Liver disease such as chronic active hepatitis or chronic persistent hepatitis.&#xD;
&#xD;
          -  Patients with a known history of HIV seropositivity.&#xD;
&#xD;
          -  QT prolongation (QTc &gt; 450 msec).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Viktor Grünwald, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Hannover, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waldkrankenhaus St. Marien</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Göttingen</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncological Practice Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Tübingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>September 28, 2012</study_first_submitted>
  <study_first_submitted_qc>November 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2012</study_first_posted>
  <last_update_submitted>February 4, 2019</last_update_submitted>
  <last_update_submitted_qc>February 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

